Clinical Trials Directory

Trials / Completed

CompletedNCT01082055

Antiarrythmic Drugs - Long-term Follow-up in the Modern Era

Retrospective Record Linkage Study to Investigate the Incidence of Complications and Follow-up Associated With Anti-arrythmic Drug Therapy

Status
Completed
Phase
Study type
Observational
Enrollment
5,000 (estimated)
Sponsor
University of Dundee · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Antiarrhythmic drugs are associated with significant side effect profiles. Amiodarone has primarily class III action and whilst it has unrivalled efficacy in management of certain arrhythmias, it has a formidable side effect profile. Complications of continued therapy include, thyroiditis, hepatitis, cholestasis, increased skin sensitivity and pulmonary fibrosis. Current prescribing guidelines recommend frequent blood tests to monitor kidney, liver and thyroid function, in addition to frequent pulmonary function tests. Sotalol is a betablocker which possesses class III action in high doses and may predispose to QT prolongation Other class I agents such as flecainide and propafenone can be associated with sudden cardiac death in certain populations, and may predispose to other arrhythmias. This study will examine the incidence of discontinuation of AAD therapy and adverse events.

Conditions

Timeline

Start date
2010-03-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2010-03-05
Last updated
2018-05-14

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01082055. Inclusion in this directory is not an endorsement.